Skip to main content
Erschienen in: Tumor Biology 4/2014

01.04.2014 | Research Article

Association between interleukin-4 -590C > T polymorphism and non-Hodgkin’s lymphoma risk

verfasst von: Cuiling Zhou, Shouyong Cui, Rongjiao Zhou, Lianfeng Dou

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Many studies were performed to assess the association between IL-4 -590C > T polymorphism and non-Hodgkin’s lymphoma (NHL) risk, but no consensus was available up to now. We conducted a meta-analysis to examine the association between IL-4 -590C > T polymorphism and NHL risk. We used odds ratios (ORs) to assess the strength of the association and 95 % confidence intervals (CIs) to give a sense of the precision of the estimate. A total of six studies were found to be eligible for meta-analyses of IL-4 -590C > T variant. Results from this study showed that IL-4 -590C > T polymorphism was not significantly associated with NHL risk under all genetic models in overall population. Further sensitivity analysis confirmed the results. In subgroup analyses stratified by race, no significant association was found in either Caucasian or mixed populations. The meta-analysis indicated that elected -590C > T polymorphism of IL-4 may not be a risk factor for NHL development.
Literatur
1.
Zurück zum Zitat Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351:2159–69.PubMedCrossRef Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351:2159–69.PubMedCrossRef
2.
Zurück zum Zitat Rosenwald A, Staudt LM. Clinical translation of gene expression profiling in lymphomas and leukemias. Semin Oncol. 2002;29:258–63.PubMedCrossRef Rosenwald A, Staudt LM. Clinical translation of gene expression profiling in lymphomas and leukemias. Semin Oncol. 2002;29:258–63.PubMedCrossRef
3.
Zurück zum Zitat Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99:4283–97.PubMedCrossRef Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99:4283–97.PubMedCrossRef
4.
Zurück zum Zitat Zhang H, Xu Y, Zhang Z, Liu R, Ma B. Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis. BMC Immunol. 2012;13:14.PubMedCentralPubMedCrossRef Zhang H, Xu Y, Zhang Z, Liu R, Ma B. Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis. BMC Immunol. 2012;13:14.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Zhang H, Ma H, Li L, Zhang Z, Xu Y. Association of methylenetetrahydrofolate dehydrogenase 1 polymorphisms with cancer: a meta-analysis. PLoS One. 2013;8:e69366.PubMedCentralPubMedCrossRef Zhang H, Ma H, Li L, Zhang Z, Xu Y. Association of methylenetetrahydrofolate dehydrogenase 1 polymorphisms with cancer: a meta-analysis. PLoS One. 2013;8:e69366.PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Zhang HT, Xu Y, Zhang ZH, Li L. Meta-analysis of epidemiological studies demonstrates significant association of PTGS2 polymorphism rs689470 and no significant association of rs20417 with prostate cancer. Genet Mol Res. 2012;11(2):1642–50.PubMedCrossRef Zhang HT, Xu Y, Zhang ZH, Li L. Meta-analysis of epidemiological studies demonstrates significant association of PTGS2 polymorphism rs689470 and no significant association of rs20417 with prostate cancer. Genet Mol Res. 2012;11(2):1642–50.PubMedCrossRef
10.
Zurück zum Zitat Serefoglou Z, Yapijakis C, Nkenke E, Vairaktaris E. Genetic association of cytokine DNA polymorphisms with head and neck cancer. Oral Oncol. 2008;44:1093–9.PubMedCrossRef Serefoglou Z, Yapijakis C, Nkenke E, Vairaktaris E. Genetic association of cytokine DNA polymorphisms with head and neck cancer. Oral Oncol. 2008;44:1093–9.PubMedCrossRef
12.
Zurück zum Zitat Noguchi E, Nukaga-Nishio Y, Jian Z, Yokouchi Y, Kamioka M, Yamakawa-Kobayashi K, et al. Haplotypes of the 5′ region of the IL-4 gene and SNPs in the intergene sequence between the IL-4 and IL-13 genes are associated with atopic asthma. Hum Immunol. 2001;62:1251–7.PubMedCrossRef Noguchi E, Nukaga-Nishio Y, Jian Z, Yokouchi Y, Kamioka M, Yamakawa-Kobayashi K, et al. Haplotypes of the 5′ region of the IL-4 gene and SNPs in the intergene sequence between the IL-4 and IL-13 genes are associated with atopic asthma. Hum Immunol. 2001;62:1251–7.PubMedCrossRef
13.
Zurück zum Zitat Andrie E, Michos A, Kalampoki V, Pourtsidis A, Moschovi M, Polychronopoulou S, et al. Genetic variants in immunoregulatory genes and risk for childhood lymphomas. Eur J Haematol. 2009;83:334–42.PubMedCrossRef Andrie E, Michos A, Kalampoki V, Pourtsidis A, Moschovi M, Polychronopoulou S, et al. Genetic variants in immunoregulatory genes and risk for childhood lymphomas. Eur J Haematol. 2009;83:334–42.PubMedCrossRef
14.
Zurück zum Zitat Wong HL, Breen EC, Pfeiffer RM, Aissani B, Martinson JJ, Margolick JB, et al. Cytokine signaling pathway polymorphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study. AIDS. 2010;24:1025–33.PubMedCentralPubMedCrossRef Wong HL, Breen EC, Pfeiffer RM, Aissani B, Martinson JJ, Margolick JB, et al. Cytokine signaling pathway polymorphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study. AIDS. 2010;24:1025–33.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Wang SS, Cerhan JR, Hartge P, Davis S, Cozen W, Severson RK, et al. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res. 2006;66:9771–80.PubMedCrossRef Wang SS, Cerhan JR, Hartge P, Davis S, Cozen W, Severson RK, et al. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res. 2006;66:9771–80.PubMedCrossRef
16.
Zurück zum Zitat Lan Q, Zheng T, Rothman N, Zhang Y, Wang SS, Shen M, et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood. 2006;107:4101–8.PubMedCentralPubMedCrossRef Lan Q, Zheng T, Rothman N, Zhang Y, Wang SS, Shen M, et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood. 2006;107:4101–8.PubMedCentralPubMedCrossRef
17.
18.
Zurück zum Zitat Zhang H, Qi C, Wang A, Yao B, Li L, Wang Y, et al. Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer. J Exp Clin Cancer Res. 2013;32:77.PubMedCentralPubMedCrossRef Zhang H, Qi C, Wang A, Yao B, Li L, Wang Y, et al. Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer. J Exp Clin Cancer Res. 2013;32:77.PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Yang J, Wang S, Zhao G, Sun B. Effect of chemokine receptors CCR7 on disseminated behavior of human T cell lymphoma: clinical and experimental study. J Exp Clin Cancer Res. 2011;30:51.PubMedCentralPubMedCrossRef Yang J, Wang S, Zhao G, Sun B. Effect of chemokine receptors CCR7 on disseminated behavior of human T cell lymphoma: clinical and experimental study. J Exp Clin Cancer Res. 2011;30:51.PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Pei JH, Luo SQ, Zhong Y, Chen JH, Xiao HW, Hu WX. The association between non-Hodgkin lymphoma and methylation of p73. Tumor Biol. 2011;32(6):1133–8.CrossRef Pei JH, Luo SQ, Zhong Y, Chen JH, Xiao HW, Hu WX. The association between non-Hodgkin lymphoma and methylation of p73. Tumor Biol. 2011;32(6):1133–8.CrossRef
21.
Zurück zum Zitat Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA. 1998;279:281–6.PubMedCrossRef Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA. 1998;279:281–6.PubMedCrossRef
22.
Zurück zum Zitat Zhuo W, Zhang L, Wang Y, Zhu B, Chen Z. CYP1A1 MspI polymorphism and acute myeloid leukemia risk: meta-analyses based on 5018 subjects. J Exp Clin Cancer Res. 2012;31:62.PubMedCentralPubMedCrossRef Zhuo W, Zhang L, Wang Y, Zhu B, Chen Z. CYP1A1 MspI polymorphism and acute myeloid leukemia risk: meta-analyses based on 5018 subjects. J Exp Clin Cancer Res. 2012;31:62.PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Dickersin K, Min YI, Meinert CL. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA. 1992;267:374–8.PubMedCrossRef Dickersin K, Min YI, Meinert CL. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA. 1992;267:374–8.PubMedCrossRef
24.
Zurück zum Zitat Cuppone F, Bria E, Vaccaro V, Puglisi F, Fabi A, Sperduti I, et al. Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: meta-regression analysis of randomized trials. J Exp Clin Cancer Res. 2011;30:54.PubMedCentralPubMedCrossRef Cuppone F, Bria E, Vaccaro V, Puglisi F, Fabi A, Sperduti I, et al. Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: meta-regression analysis of randomized trials. J Exp Clin Cancer Res. 2011;30:54.PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Wang XT, Wei WY, Kong FB, Lian C, Luo W, Xiao Q, et al. Prognostic significance of Cdx2 immunohistochemical expression in gastric cancer: a meta-analysis of published literatures. J Exp Clin Cancer Res. 2012;31:98.PubMedCentralPubMedCrossRef Wang XT, Wei WY, Kong FB, Lian C, Luo W, Xiao Q, et al. Prognostic significance of Cdx2 immunohistochemical expression in gastric cancer: a meta-analysis of published literatures. J Exp Clin Cancer Res. 2012;31:98.PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867–72.PubMedCrossRef Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867–72.PubMedCrossRef
Metadaten
Titel
Association between interleukin-4 -590C > T polymorphism and non-Hodgkin’s lymphoma risk
verfasst von
Cuiling Zhou
Shouyong Cui
Rongjiao Zhou
Lianfeng Dou
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1394-7

Weitere Artikel der Ausgabe 4/2014

Tumor Biology 4/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.